On 9 October 2015, orphan designation (EU/3/15/1565) was granted by the European Commission to PBS Regulatory Consulting Group Limited, United Kingdom, for 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide for the treatment of hepatocellular carcinoma.

The sponsorship was transferred to Southwood Research Ltd in March 2020.

This medicine is now known as namodenoson. 

Key facts

Active substance
2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Southwood Research Ltd
Gustav Mahlerplein 2 
1082 MA Amsterdam  
The Netherlands 
Tel. +31 2079 97362

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating